The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $999,998 Project Grant to Curza Inc., a biotechnology company, to develop a new class of broad-spectrum antibiotics targeting multidrug-resistant Gram-negative pathogens. The project aims to optimize lead compounds, conduct in vivo pharmacokinetic and efficacy evaluations, and prepare a lead antibiotic candidate for potential IND-enabling studies. This represents the latest in a series of NIAID grants totaling approximately $2 million awarded to Curza between 2020-2024 to advance its CZ-02 antibiotic development platform, which focuses on novel compounds that selectively inhibit bacterial protein synthesis while minimizing cytotoxicity to mammalian cells. The goal is to deliver a new antibiotic candidate capable of treating challenging Gram-negative infections caused by pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii.
Generated 1/28/25, 6:55 AM